Search Results

A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD-(L)1 therapy based on PD-L1 negative disease (ROSETTA Breast-01) MOA: BNT327 (pumitamig) is a bispecific antibody that targets PD-L1 and VEGF-A. Key Eligibility: Confirmed…

Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan Maintenance With or Without Bevacizumab vs Standard of Care in Participants With Newly Diagnosed Advanced HRD Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOT-ov85/GOG-3102) MOA: Sacituzumabtirumotecan (Sac-TMT) is a TROP2 targeting ADC with a TOP1i payload. Key Eligibility Confirmed FIGO Stage III or IV epithelial OC/FT/PPC…

A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301) MOA: Atebimetinib (IMM-1 104) is a deep cyclic dual inhibitor of MEK1 and MEK2 Key Eligibility: Subjects’…

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (Protocol v.00) MOA: Dabrafenib is a RAF kinase inhibitor. Trametinib is an allosteric inhibitor of MEK1/2 and kinase activity. Key Eligibility: Documented BRAF V600E mutation-positive solid tumor Study participants previously not treated…

A Global, Phase 3, Randomized, Multicenter, Open-label Study ToEvaluate The Efficacy And Safety Of Firmonertinib Compared WithInvestigator’s Choice Of Osimertinib Or Afatinib As First-line Treatment InParticipants Who Have Locally Advanced Or Metastatic Non-small-cellLung Cancer With Epidermal Growth Factor Receptor P-loop And AlphaC-helix Compressing (PACC) Uncommon Mutations (ALPACCA) MOA: Firmonertinib is an oral EGFR inhibitor with…

A Phase 3 Multicenter Double-blind Randomized Study Of Taletrectinib Versus Placebo In Patients With ROS1-fusion Positive Stage IB-IIIA Non-small Cell Lung Cancer Who Have Undergone Complete Tumor Resection (TRUST-IV) MOA: Taletrectinib (AB-106 or DS-6051b) is a ROS1 tyrosine kinase inhibitor (TKI) effective against ROS1 and acquired resistance mutations. Key Eligibility: Histologically confirmed stage IB, II,…